WHAT IS CLAIMED IS:

1. Use of a viral vector for preparation of a medicament for the treatment of a malignant glioma in a subject in need thereof, said viral vector comprising:
(i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c); and
(ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter,
wherein the second polynucleotide sequence is operably linked to the first polynucleotide sequence.

2. The use of claim 1, wherein said first polynucleotide comprises (i) the sequence set forth in SEQ ID NO: 2 and the sequence set forth in SEQ ID NO: 3 or
(ii) the sequence set forth in SEQ ID NO: 4.

3. The use of any one of claims 1 or 2, wherein said promoter comprises the sequence set forth in SEQ ID NO: 12.

4. The use of any one of claims 1 or 2, wherein said promoter comprises the sequence set forth in SEQ ID NO: 13.

5. The use of any one of claims 1-4, wherein the viral vector is an adenoviral vector.

6. The use of claim 5, wherein said adenoviral vector is a non-replicating adenoviral vector.

7. The use of claim 5, wherein said adenoviral vector is an adenovirus serotype 5 vector.

8. The use of any one of claims 1 or 2 and 5-7, wherein said promoter comprises at least one copy of the sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof.

9. The use of claim 8, wherein said promoter comprises at least two copies of the sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof.

10. The use of any one of claims 1 or 2 and 5-9, wherein said promoter comprises the sequence set forth in SEQ ID NO: 8 or the complementary sequence thereof.

11. The use of any one of claims 1 or 2 and 5-7, wherein said promoter comprises the sequence set forth in SEQ ID NO: 7 or the complementary sequence thereof.

12. The use of any one of claims 1 or 2 and 5-11, wherein said promoter comprises the hypoxia response element (HRE) set forth in SEQ ID NO: 5.

13. The use of any one of claims 1-12, wherein the viral vector consists of the sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 10.

14. The use of any one of claims 1-13, wherein the malignant glioma is selected from the group consisting of glioblastoma, astrocytoma, oligodendroglioma, and ependymoma, and juvenile pilocystic astrocytoma.

15. The use of any one of claims 1-14, wherein said viral vector is for intravenous administration.

16. The use of the any one of claims 1-14, wherein said viral vector is for local administration.

17. The use of the any one of claims 1-14, wherein said viral vector is for systemic administration.

18. The use of any one of claims 1-17, wherein said viral vector is for administration in at least two doses.

19. The use of one of claims 1-17, wherein said viral vector is for administration in at least three doses.

20. The use of claim 1, wherein said first polynucleotide comprises the sequence set forth in SEQ ID NO: 4, said second polynucleotide comprises the sequence set forth in SEQ ID NO: 7, said viral vector is a non-replicating adenovirus serotype 5 vector, said malignant glioma is gliobastoma, and said viral vector is formulated for intravenous administration.

21. A viral vector for use in preparation of a medicament for the treatment of a malignant glioma in a subject in need thereof, said viral vector comprising:
(i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c); and
(ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter,
wherein the second polynucleotide sequence is operably linked to the first polynucleotide sequence.

22. A viral vector for use in the treatment of a malignant glioma in a subject in need thereof, said viral vector comprising:
(i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c); and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter, wherein the second polynucleotide sequence is operably linked to the first polynucleotide sequence.

23. The viral vector for use of claim 21 or 22, wherein said first polynucleotide comprises (i) the sequence set forth in SEQ ID NO: 2 and the sequence set forth in SEQ ID NO: 3 or (ii) the sequence set forth in SEQ ID NO: 4.

24. The viral vector for use of any one of claims 21-23, wherein said promoter comprises the sequence set forth in SEQ ID NO: 12.

25. The viral vector for use of any one of claims 21-23, wherein said promoter comprises the sequence set forth in SEQ ID NO: 13.

26. The viral vector for use of any one of claims 21-25, wherein the viral vector is an adenoviral vector.

27. The viral vector for use of claim 26, wherein said adenoviral vector is a non-replicating adenoviral vector.

28. The viral vector for use of claim 26, wherein said adenoviral vector is an adenovirus serotype 5 vector.

29. The viral vector for use of any one of claims 21-23 and 26-28, wherein said promoter comprises at least one copy of the sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof.

30. The viral vector for use of claim 29, wherein said promoter comprises at least two copies of the sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof.

31. The viral vector for use of any one of claims 21-23 and 26-30, wherein said promoter comprises the sequence set forth in SEQ ID NO: 8 or the complementary sequence thereof.

32. The viral vector for use of any one of claims 21-23 and 26-28, wherein said promoter comprises the sequence set forth in SEQ ID NO: 7 or the complementary sequence thereof.

33. The viral vector for use of any one of claims 21-23 and 26-32, wherein said promoter comprises the hypoxia response element (HRE) set forth in SEQ ID NO: 5.

34. The viral vector for use of any one of claims 21-33, wherein the viral vector consists of the sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 10.

35. The viral vector for use of any one of claims 21-34, wherein the malignant glioma is selected from the group consisting of glioblastoma, astrocytoma, oligodendroglioma, and ependymoma, and juvenile pilocystic astrocytoma.

36. The viral vector for use of any one of claims 21-35, wherein said viral vector is for intravenous administration.

37. The viral vector for use of the any one of claims 21-35, wherein said viral vector is for local administration.

38. The viral vector for use of the any one of claims 21-35, wherein said viral vector is for systemic administration.

39. The viral vector for use of any one of claims 21-38, wherein said viral vector is for administration in at least two doses.

40. The viral vector for use of one of claims 21-38, wherein said viral vector is for administration in at least three doses.

41. The viral vector for use of claim 21 or claim 22, wherein said first polynucleotide comprises the sequence set forth in SEQ ID NO: 4, said second polynucleotide comprises the sequence set forth in SEQ ID NO: 7, said viral vector is a non-replicating adenovirus serotype 5 vector, said malignant glioma is gliobastoma, and said viral vector is formulated for intravenous administration.